AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday it ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

The company’s partnership with Daiichi Sankyo Europe has also driven substantial growth in prescription sales in Europe. Furthermore, Esperion is expanding into new international markets, with ...

Carebook Technologies Inc. ("Carebook" or the "Company") (XETR: PMM1), a leading Canadian provider of innovative digital health solutions, will release its financial results for the quarter ended ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Dato-DXd: Daiichi Sankyo, Inc. Datopotamab deruxtecan (Dato-DXd) is an investigational currently in Phase III for HR-positive ...

MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-stage ...